April, 2022
THE POWER OF TCR2
Read more
March, 2022
HYPERTROPHIC SCAR FORMATION
Read more
Published, 2022
A Comprehensive Preclinical Study: Molecular Therapy: Original Article. Methods & Clinical Development. A comprehensive preclinical study supporting clinical trial of oncolytic chimeric poxvirus CF33-hNIS-anti-PD-L1 to treat breast cancer.
Check Out the Article
January, 2022
BIOCOMPATIBILITY AND DEVICES
Read more
December, 2021
HAPPY HOLIDAYS FROM CBI
Read more
December, 2021
QUALITY MANAGEMENT AT CBI
Read more
November, 2021
DERMAL BURN MODELING
Read more
September, 2021
TOXICOLOGY IN RODENTS
Read more
October, 2021
Genesis Biotechnology Group Acquires BioBlocks to Grow the Preclinical Chemistry Services Portfolio of Genesis Drug Discovery & Development (GD3)
Read more
September, 2021
Genesis Drug Discovery & Development Appoints Laura Sailor Veteran CRO Business Development Leader as Director of Business Development
Read more
September, 2021
Genesis Drug Discovery & Development Appoints Anthony Rohr as Chief Operating Officer
Read more
August, 2021
SUBCUTANEOUS IMPLANT PROCEDURES
Read more
July, 2021
TISSUE CROSS-REACTIVITY STUDIES
Read more
June, 2021
WELCOME TO CBI VIRTUAL TOUR VIDEO 2021
Read more
April, 2021
SURGICAL MODELS FOR PRECLINICAL TESTING
Read more
March, 2021
INTRAOCULAR LENS VIDEO
Read more
February, 2021
SPINAL TRAUMA IN RODENTS
Read more
January, 2021
PRECLINICAL ANIMAL MODELS OF COVID-ARDS
Read more
January, 2021
CAROTID ARTERY STUDIES
Read more
January, 2021
Genesis Drug Discovery and Development expands its presence in the clinical space by acquiring STATKING Clinical Services
Read more
December, 2020
Genesis Biotechnology Group announces second year of CRO relationship with Yale University
Read more
December, 2020
ONCOLYTIC VIRAL VACCINE STUDIES Read more
November, 2020
OTOTOXICITY STUDIES Read more
October, 2020
TISSUE CROSS-REACTIVITY STUDIES Read more
September, 2020
BLADDER CANCER STUDIES AT CBI. Read more
August, 2020
CBI JOINES GENESIS – FROM Dr. CAROL MESCHTER Read more
August, 2020
Genesis Biotechnology Group acquires Comparative Biosciences, Inc. (CBI) to add GLP Toxicology and Safety Pharmacology to its portfolio of Preclinical Services
Read more
August, 2020
IMIQUIMOD-INDUCED PSORIASIS Read more
July, 2020
ANIMALS AND COVID-19 RESEARCH AT CBI
Read more
June, 2020
OPEN FOR BUSINESS AT CBI
Read more
May, 2020
BUSINESS AS USUAL AROUND HERE
Read more
April, 2020
FROM THE DESK OF DR. CAROL MESCHTER
Read more
March, 2020
CONTINUING OUR SERVICES TO THE HIGHEST LEVELS AT CBI
Read more
February, 2020
CORONAVIRUS TREATMENT STUDIES AT CBI
Read more
January, 2020
ONCOLYTIC VIRAL VACCINE AT CBI
Read more
January, 2019
Intraocular Lens Implantation Studies
Read more
November, 2018
Pompe Disease Studies
Read more
October, 2018
Fibrosis Inflammation
Read more
September, 2018
Skin Closure Published Article 2018
Read more
August, 2018
Pulmonary Studies
Read more
July, 2018
Wound Healing Studies
Read more
June, 2018
Central Nervous System Studies
Read more
May, 2018
Success at ARVO 2018 – Honolulu, Hawaii
Read more
April 29 – May 3, 2018
Visit CBI at ARVO 2018 – Annual Meeting
Read more
March, 2018
Burns and Dermatitis Studies
Read more
February, 2018
Visit CBI at SOT 2018 – Annual Meeting and Tox Expo
Read more
January, 2018
CBI Congratulates Meridigen Biotech Co. on a Successful IND Project
Read more
